U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly and Company Eli Lilly’s oral SERD Inluriyo passes muster with FDA in breast cancer Fierce Pharma Eli Lilly wins approval of imlunestrant for breast cancer Seeking Alpha Recon: RFK Jr. launches review of mifepristone; FDA approves Lilly’s advanced breast cancer drug Regulatory Affairs Professionals Society | …
Read More »